These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9037273)

  • 1. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients.
    Wittes JT; Kelly A; Plante KM
    Transplant Proc; 1996 Dec; 28(6 Suppl 2):17-24. PubMed ID: 9037273
    [No Abstract]   [Full Text] [Related]  

  • 2. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
    Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with intravenous immune globulin.
    Snydman DR
    Transplant Proc; 1991 Apr; 23(2 Suppl 1):20-5. PubMed ID: 1647560
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection in bone marrow transplant recipients: use of intravenous gamma globulin as a prophylactic and therapeutic agent.
    Kapoor N; Copelan EA; Tutschka PJ
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3095-6. PubMed ID: 2539686
    [No Abstract]   [Full Text] [Related]  

  • 7. Critical evaluation of agents used in the treatment and prevention of cytomegalovirus infection in immunocompromised patients.
    Meyers JD
    Transplant Proc; 1991 Jun; 23(3 Suppl 3):139-42, discussion 142-3. PubMed ID: 1648819
    [No Abstract]   [Full Text] [Related]  

  • 8. Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease.
    Glowacki LS; Smaill FM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1408-10. PubMed ID: 8382863
    [No Abstract]   [Full Text] [Related]  

  • 9. Issues concerning the use of intravenous immunoglobulins for the immunoprophylaxis of cytomegalovirus infections in allogeneic bone marrow transplant recipients.
    Emanuel D
    Monogr Allergy; 1988; 23():216-24. PubMed ID: 2838745
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of cytomegalovirus disease in transplant recipients.
    Pidgeon GB; Bailey RR
    N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study Group.
    Werner BG; Snydman DR; Freeman R; Rohrer R; Tilney NL; Kirkman RL
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1441-3. PubMed ID: 8382875
    [No Abstract]   [Full Text] [Related]  

  • 12. Defining an optimal regimen for cytomegalovirus prophylaxis in organ transplant recipients.
    Paya CV
    Transplant Proc; 1996 Dec; 28(6 Suppl 2):9-11. PubMed ID: 9037269
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytomegalovirus infection in seromismatched lung transplant recipients with and without prophylaxis with CMV immunoglobulin.
    Kathawalla SA; Stillwell PC; Gordon S; Haug M; Perl M; Arroliga AC; Mehta AC; Avery R; Kirby T
    Transplant Proc; 1996 Dec; 28(6 Suppl 2):16. PubMed ID: 9037272
    [No Abstract]   [Full Text] [Related]  

  • 14. New developments in cytomegalovirus prevention and management.
    Snydman DR; Rubin RH; Werner BG
    Am J Kidney Dis; 1993 Feb; 21(2):217-28. PubMed ID: 8381578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMV immunoglobulin for prevention of pneumonitis after BMT.
    Klingemann HG; Phillips GL
    Bone Marrow Transplant; 1988 May; 3(3):235-6. PubMed ID: 2844345
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical aspects and management of cytomegalovirus infection.
    Sissons JG; Carmichael AJ
    J Infect; 2002 Feb; 44(2):78-83. PubMed ID: 12076065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of CMV infection in transplant patients.
    Fishman JA
    Transpl Infect Dis; 1999; 1 Suppl 1():35-9. PubMed ID: 11565586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection in transplant patients.
    Betts RF
    Prog Med Virol; 1982; 28():44-64. PubMed ID: 6283602
    [No Abstract]   [Full Text] [Related]  

  • 19. [Commercial methods for the diagnosis of CMV infection after organ or bone marrow transplantation].
    Schvoerer E; Stoll-Keller F
    Ann Biol Clin (Paris); 2002; 60(4):463-7. PubMed ID: 12147450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination protocols for prevention of CMV disease in the high risk transplant patient.
    Martin M
    Transplant Proc; 1996 Dec; 28(6 Suppl 2):12-3. PubMed ID: 9037270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.